Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Treasury Shares (2016 - 2025)

Historic Treasury Shares for Arrowhead Pharmaceuticals (ARWR) over the last 1 years, with Q4 2025 value amounting to $53.2 million.

  • Arrowhead Pharmaceuticals' Treasury Shares changed N/A to $53.2 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.2 million, marking a year-over-year change of. This contributed to the annual value of $53.2 million for FY2025, which is N/A changed from last year.
  • Per Arrowhead Pharmaceuticals' latest filing, its Treasury Shares stood at $53.2 million for Q4 2025.
  • In the past 5 years, Arrowhead Pharmaceuticals' Treasury Shares registered a high of $6.0 million during Q2 2025, and its lowest value of $2.7 million during Q3 2025.
  • Moreover, its 5-year median value for Treasury Shares was $4.3 million (2023), whereas its average is $4.3 million.
  • Over the last 5 years, Arrowhead Pharmaceuticals' Treasury Shares had its largest YoY gain of 1890.68% in 2025, and its largest YoY loss of 4745.03% in 2025.
  • Over the past 5 years, Arrowhead Pharmaceuticals' Treasury Shares (Quarter) stood at $3.6 million in 2021, then rose by 10.63% to $4.0 million in 2022, then rose by 15.65% to $4.6 million in 2023, then rose by 10.45% to $5.1 million in 2024, then tumbled by 47.45% to $2.7 million in 2025.
  • Its last three reported values are $2.7 million in Q4 2025, $2.7 million for Q3 2025, and $6.0 million during Q2 2025.